<DOC>
	<DOCNO>NCT00147771</DOCNO>
	<brief_summary>Morphea hard treat . In small number adult patient , Imiquimod proven beneficial decrease thickness morphea plaque , improve appearance . There study date prove safety efficacy child disease . We propose conduct pilot study assess potential efficacy relative safety Imiquimod child plaque morphea .</brief_summary>
	<brief_title>Imiquimod Children With Plaque Morphea</brief_title>
	<detailed_description>Design : Prospective , open label , pilot study Settings : The Hospital Sick Children , Specialized Morphea Clinic Study population : - Children 6-18 year age - Plaque morphea measure less 10 cm2 diameter ( child multiple lesion , one treat ) Intervention : Topical imiquimod apply 3-5 time week 6 month Outcome measure : Decrease thickness skin clinical score ultrasonography Duration study : 12 month ( 2 baseline visit , 1 intervention visit , 5 follow-up visit )</detailed_description>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Age diagnosis 6 18 year age Morphea plaques Female subject childbearing potential must negative urine pregnancy test Signed consent/assent form Exclusion criterion : Children receive topical corticosteroid , tacrolimus , vitamin D derivative ( calcipotriol , calcipotriolbetamethasone dipropionate ) affect area previous four week Children previously treat Imiquimod affect area Children demonstrable ultrasonographic change baseline evaluation Children evidence skin breakdown propose area treat time enrollment due potential increase absorption medication impair skin barrier Female subject childbearing potential agree practice effective birth control method duration study Children are/were ( past 6 month ) treat systemic medication methotrexate and/or systemic corticosteroid Comorbidities : systemic sclerosis , juvenile rheumatoid arthritis , systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>localize scleroderma</keyword>
	<keyword>morphea</keyword>
	<keyword>imiquimod</keyword>
	<keyword>pediatrics</keyword>
</DOC>